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Tumor Necrosis Factor Alpha Is a Key Mediator of Gut Inflammation
Seen in Amebic Colitis in Human Intestine in the SCID
Mouse-Human Intestinal Xenograft Model of Disease
Zhi Zhang,1 Sajan Mahajan,1 Xiaochung Zhang,1 and Samuel L. Stanley, Jr.1,2*
Departments of Medicine1 and Molecular Microbiology,2 Washington University School of Medicine, St. Louis, Missouri
Received 24 January 2003/Returned for modification 21 February 2003/Accepted 6 June 2003
We used Entamoeba histolytica infection in human intestinal xenografts to study the roles interleukin-1 (IL-1)
and tumor necrosis factor alpha (TNF-) in the pathogenesis of amebic colitis. We found that blockade of
TNF- reduced inflammation and intestinal damage in amebic infection, while inhibition of IL-1 reduced
cytokine production but had less marked effects on inflammation and disease.
Entamoeba histolytica is a parasitic protozoan that causes
amebic colitis and amebic liver abscess in humans. Studies with
severe combined immunodeficient mice with human intestinal
xenografts (SCID-HU-INT mice) have shown that E. histo-
lytica infection leads to gut inflammation with intestinal pro-
duction of interleukin-1 (IL-1), IL-8, and cycloxygenase-2
(6, 9). E. histolytica-induced gut inflammation is mediated
through the action of NF-, and inhibition of the synthesis of
the p65 subunit of NF- reduces IL-1 and IL-8 levels and
decreases gut inflammation and tissue damage in human in-
testinal xenografts infected with E. histolytica (7). Treatment
with a specific inhibitor of cycloxygenase-2 also reduces inflam-
mation and epithelial damage in amebic colitis in SCID-HU-
INT mice (9). These data suggest that a significant component
of the early tissue damage seen in this model of amebic colitis
arises from the host inflammatory response to E. histolytica.
One of the important mediators of intestinal inflammation in
inflammatory bowel disease is tumor necrosis factor alpha
(TNF-) (4, 5). In a recent transcriptional analysis of human
colonic xenografts infected with E. histolytica, we found in-
creased expression of a number of genes known to be activated
by TNF- (Z. Zhang and S. L. Stanley, Jr., unpublished data).
These findings led us to determine whether the blockade of
either (i) TNF- with a chimerized monoclonal antibody to
TNF- (Infliximab or Remicade; Centocor Inc., Malvern, Pa.)
or (ii) IL-1 activity with a recombinant human IL-1 receptor
antagonist (IL-1ra; Anakinra or Kineret; Amgen Inc., Thou-
sand Oaks, Calif.) would alter gut inflammation and tissue
damage during amebic infection.
Human intestinal xenografts were placed into the rear flanks
and suprascapular regions of SCID mice (6 to 8 weeks of age)
as previously described (6). Grafts were allowed to develop for
at least 8 weeks before use. Human intestinal xenografts were
infected with E. histolytica trophozoites with direct intralumi-
nal inoculation of 106 HM1:IMSS trophozoites per 100 l of
TYI-S-33 medium (5). SCID-HU-INT mice were sacrificed
approximately 24 h after E. histolytica infection of human in-
testinal xenografts, and serum and tissue were obtained for
cytokine, myeloperoxidase (MPO), intestinal permeability, and
histologic assays (7). A group of 10 SCID-HU-INT mice were
treated by intraperitoneal injection of 100 l of a 13.3-mg/ml
solution of the IL-1ra Anakinra in sterile phosphate-buffered
saline (PBS) 3 h before an amebic challenge, 8 h after an
amebic challenge, and 20 h after an amebic challenge. A con-
trol group of 10 SCID-HU-INT mice were treated with PBS
alone on the same schedule and challenged with an identical
dose of E. histolytica HM1:IMSS trophozoites. Serum samples
from five Anakinra-treated and five untreated SCID-HU-INT
mice were drawn 10.5 h after the first injection and assayed for
human IL-1ra activity with an enzyme-linked immunosorbent
assay (ELISA; R&D Systems Inc., Minneapolis, Minn.) in ac-
cordance with the manufacturer’s protocol. Serum obtained
from the SCID-HU-INT mice treated with IL-1ra showed
mean IL-1ra levels of 371  127 ng/ml, while serum from the
untreated SCID-HU-INT mice with an E. histolytica graft in-
fection at the same time point showed a mean level of 1.9 1.7
ng/ml.
A group of 14 SCID-HU-INT mice received 200 g of In-
fliximab (Remicade), a chimerized anti-TNF-monoclonal an-
tibody, in 100 l of sterile PBS by intraperitoneal injection 24 h
prior to a challenge of the human intestinal xenografts with
HM1:IMSS E. histolytica trophozoites. A control group of 11
SCID-HU-INT mice received 100 l of sterile PBS alone 24 h
prior to a challenge with E. histolytica trophozoites. One of the
control mice died prior to sacrifice, and fresh tissues and serum
could not be obtained for analysis. Finally, a group of 10
SCID-HU-INT mice received both Infliximab and Anakinra
on the same dosage schedules described above before a chal-
lenge with E. histolytica trophozoites. A control group of 10
SCID-HU-INT mice received sterile PBS on the same dosage
schedule before a challenge with E. histolytica trophozoites.
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We have previously shown that increased levels of both
human IL-1 and IL-8 can be detected in human intestinal
xenografts infected with E. histolytica trophozoites. IL-1 lev-
els were measured from segments of human intestinal xeno-
grafts by ELISA as previously described (7). We found that
pretreatment of SCID-HU-INT mice with IL-1ra significantly
inhibited the increase in IL-1 usually associated with E. his-
tolytica infection (Fig. 1A) (P  0.01). A statistically significant
FIG. 1. Effect of IL-1 blockade or TNF- blockade on gut inflammation and damage in human colonic xenografts infected with E. histolytica.
Values are the means  standard deviations for E. histolytica-infected human colonic xenografts from 14 anti-TNF--treated SCID-HU-INT mice
(anti-TNF-), 10 IL-1ra-treated SCID-HU-INT mice (IL-1ra), 10 mice treated with both anti-TNF- and IL-1ra (anti-TNF- and IL-1ra), and 10
donor-matched, untreated SCID-HU-INT mice for each experimental group (control). Mean levels of IL-1, expressed as picograms of IL-1 per
milligram of total protein (A), were significantly lower (two-tailed t test) in human colonic xenografts from anti-TNF--treated (P  0.01),
IL-1ra-treated (P  0.01), or anti-TNF-- and IL-1ra-treated SCID-HU-INT mice (P  0.01) than in the matched untreated group. Mean levels
of IL-8, expressed as picograms of IL-8 per microgram of total protein (B), were significantly lower in human colonic xenografts from
anti-TNF--treated (P  0.02), IL-1ra-treated (P  0.01), or anti-TNF-- and IL-1ra-treated SCID-HU-INT mice (P  0.01) than in the matched
untreated group. Mean levels of MPO, expressed as units of MPO per milligram of total protein (C), were significantly lower in anti-TNF--treated
SCID-HU-INT mice than in untreated SCID-HU-INT mice (P  0.02) and in anti-TNF-- and IL-1ra-treated SCID-HU-INT mice than in
untreated mice (P  0.01) but did not significantly differ between untreated SCID-HU-INT mice and mice receiving IL-1ra alone (P  0.138).
Mean levels of FITC in serum, expressed as nanograms of FITC per milliliter per square millimeter (D), were significantly lower in E.
histolytica-infected human colonic xenografts from SCID-HU-INT mice treated with anti-TNF- than in E. histolytica-infected colonic xenografts
from untreated SCID-HU-INT mice (P  0.02) and in SCID-HU-INT mice treated with both IL-1ra and anti-TNF- (P  0.01 compared to
untreated mice) but did not differ significantly between IL-1ra-treated SCID-HU-INT mice and untreated SCID-HU-INT mice (P  0.45).
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decrease in IL-1 production was also seen in the E. histolytica-
infected SCID-HU-INT mice treated with the anti-TNF-
monoclonal antibody (Fig. 1A) (P  0.01). Combination ther-
apy of SCID-HU-INT mice with both IL-1ra and the anti-
TNF- antibody also reduced the IL-1 levels in E. histolytica-
infected human colonic xenografts (P 0.01 compared with E.
histolytica-infected human colonic xenografts from untreated
SCID-HU-INT mice), but no obvious additive effect of com-
bined treatment was detectable. Similar results were obtained
for IL-8 (Fig. 1B) (measured by ELISA as previously described
[5]) with E. histolytica-infected human colonic xenografts from
IL-1ra-treated SCID-HU-INT mice showing levels of IL-8 that
were 75% lower than those seen in E. histolytica-infected hu-
man intestinal xenografts from untreated SCID-HU-INT mice
(P  0.01). Levels of IL-8 were also lower in human colonic
xenografts from E. histolytica-infected SCID-HU-INT mice
treated with anti-TNF- (P  0.02 compared to controls) and
in those from E. histolytica-infected SCID-HU-INT mice
treated with both anti-TNF- and IL-1ra (P  0.01 compared
to controls).
We can quantify one component of inflammation by mea-
suring neutrophil influx into human intestinal xenografts with
an assay of MPO activity (7). Previous experiments in our
laboratory have shown that amebic infection in the SCID-HU-
INT system is associated with neutrophil infiltration into the
lumen and lamina propria of the human intestinal xenograft
(7). We found that while treatment of SCID-HU-INT mice
with human IL-1ra lowered mean MPO levels in E. histolytica-
infected human intestinal xenografts (Fig. 1C), the difference
did not reach statistical significance (P  0.138). However,
pretreatment of SCID-HU-INT mice with anti-TNF- de-
creased neutrophil influx into E. histolytica-infected human
intestinal xenografts, resulting in MPO levels that were signif-
icantly lower than those detected in E. histolytica-infected hu-
man intestinal xenografts from untreated SCID-HU-INT mice
(Fig. 1C) (P  0.02). Pretreatment with both IL-1ra and anti-
TNF- also significantly lowered MPO levels in E. histolytica-
infected xenografts from SCID-HU-INT mice (P  0.01).
We measured changes in the permeability of the human
colonic xenografts to fluoresceinated dextrans (fluorescein iso-
thiocyanate [FITC]-dextran) to quantify damage to the intes-
tinal permeability barrier. Uninfected human intestinal xeno-
grafts are relatively impermeable to FITC-dextran, while E.
histolytica-mediated damage permits passage of FITC-dextran
from the lumen of the human intestinal xenograft to the serum
of the SCID-HU-INT mouse (7). Pretreatment of SCID-HU-
INT mice with IL-1ra led to mean levels of FITC-dextran in
the serum of E. histolytica-infected mice that did not differ
significantly (P  0.45) from those seen in the serum of un-
treated SCID-HU-INT mice with E. histolytica-infected human
intestinal xenografts (Fig. 1D). In contrast, pretreatment of
FIG. 2. Morphological findings on E. histolytica-infected human co-
lonic xenografts from SCID-HU-INT mice. Photomicrographs of he-
matoxylin-and-eosin-stained sections of E. histolytica-infected human
colonic xenografts from an untreated SCID-HU-INT mouse (A), an
anti-TNF--treated SCID-HU-INT mouse (B), and an IL-1ra-treated
mouse (C) are shown. Extensive mucosal destruction and inflamma-
tion with neutrophil infiltration and multiple E. histolytica trophozoites
(arrows) that have invaded the mucosa and submucosal tissues are
visible in the section from the untreated SCID-HU-INT mouse (A). In
the E. histolytica-infected human colonic xenograft from the anti-TNF-
-treated mouse, extensive mucosal damage and multiple invading E.
histolytica trophozoites are also visible (arrows) but no marked cellular
infiltrate is present (B). In the E. histolytica-infected human colonic
xenograft from the IL-1ra-treated mouse (C), extensive mucosal dam-
age and hemorrhage are present near a single E. histolytica trophozoite
(arrow) but no marked neutrophilic infiltration is apparent. Original
magnification of all three panels, 	400.
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SCID-HU-INT mice with anti-TNF- reduced the damage to
the intestinal permeability barrier in human intestinal xeno-
grafts infected with E. histolytica. As shown in Fig. 1D, FITC-
dextran levels were significantly lower in the serum of SCID-
HU-INT mice that had been treated with anti-TNF- (P 
0.02) than in that of uninfected controls. Pretreatment of
SCID-HU-INT mice with both IL-1ra and TNF- significantly
reduced serum FITC-dextran levels as well, consistent with
reduced damage to the intestinal permeability barrier in hu-
man intestinal xenografts from treated SCID-HU-INT mice (P
 0.01). Examination of histologic sections from human intes-
tinal xenografts from each of the three groups showed evi-
dence of E. histolytica-mediated tissue damage in almost all
xenografts. Neutrophil infiltration into the mucosal and sub-
mucosal tissues accompanied E. histolytica invasion in the con-
trol (untreated) E. histolytica-infected human intestinal xeno-
grafts (Fig. 2A) However, sections from E. histolytica-infected
human intestinal xenografts from SCID-HU-INT mice that
had received the anti-TNF- monoclonal antibody showed ar-
eas of mucosal invasion without marked neutrophil infiltration
(Fig. 2B). Some increased cellular infiltrate was seen in the
mucosal regions in sections from E. histolytica-infected SCID-
HU-INT mice that had received IL-1ra (Fig. 2C), but neutro-
philic infiltration appeared less prominent than that seen in E.
histolytica-infected human intestinal xenografts from untreated
SCID-HU-INT mice. Histologic findings on intestinal xeno-
grafts infected with E. histolytica trophozoites from SCID-HU-
INT mice pretreated with both IL-1ra and anti-TNF- did not
differ from those on xenografts from mice treated with anti-
TNF- alone (data not shown).
The efficacy of anti-TNF- in inhibiting gut inflammation in
this model raised the question of whether human or murine
TNF- can be detected in human colonic xenografts or the
serum of E. histolytica-infected or control SCID-HU-INT
mice. Neither human nor murine TNF- was detectable by
specific ELISAs (Pharmingen OptEIA Human TNF- Set and
Pharmingen OptEIA Mouse TNF-Mono/Mono Set; BD Bio-
sciences, San Diego, Calif.) in either the serum or human
colonic xenografts from uninfected SCID-HU-INT mice (data
not shown). Murine TNF- was detectable in the human co-
lonic xenografts of SCID-HU-INT mice after E. histolytica
infection (Table 1), and lower levels were seen in mice treated
with IL-1ra and anti-TNF-. Human TNF- was detectable in
the colonic xenografts of E. histolytica-infected SCID-HU-INT
mice at low levels and was decreased in E. histolytica-infected
human colonic xenografts from IL-1ra- and anti-TNF--
treated mice, but the difference did not reach statistical signif-
icance. We were not able to detect murine or human TNF- in
the serum of E. histolytica-infected SCID-HU-INT mice (data
not shown). These data indicate that both human and murine
TNF- can be detected in E. histolytica-infected human colonic
xenografts, probably secondary to production from epithelial
cells or fibroblasts of human origin and influxing inflammatory
cells of murine origin.
Both interleukin-1 and TNF- have been linked to gut in-
flammation in animal models of disease and in humans (1, 2, 4,
5). Blockade of IL-1 activity with IL-1ra led to decreased colitis
in a rabbit model of infection, while animals with a targeted
disruption of the interleukin-1-converting enzyme (ICE) gene
show resistance to the development of colitis (2, 3, 8). We have
previously shown that IL-1 levels are increased in human
intestinal xenografts infected with E. histolytica (6) and that E.
histolytica cysteine proteinases are capable of mimicking the
action of ICE and can cleave and activate pIL-1 to form the
active mature cytokine (11), suggesting that IL-1 could play a
role in the inflammation associated with amebic colitis. We
found that administration of IL-1ra inhibited the increase in
IL-1 and IL-8 that normally accompanies amebic infection in
the SCID-HU-INT model of disease. Given the known role of
IL-1 in stimulating its own production, as well as that of IL-8,
these data are consistent with the idea that IL-1 is a key
mediator in stimulating cytokine production in this system.
However, while there was a trend toward decreased inflamma-
tion and tissue damage in E. histolytica-infected human intes-
tinal xenografts from IL-1ra-treated SCID-HU-INT mice, the
results were not statistically significant. This suggests that
blockade of IL-1 alone cannot completely inhibit inflammation
in this system, and other mediators may be important compo-
nents of the E. histolytica-induced inflammatory response. One
obvious candidate is TNF-, which has been strongly linked to
gut inflammation in several forms of colitis (4). A chimerized
monoclonal antibody to TNF- (Infliximab) is highly effective
in treating the intestinal inflammation seen in Crohn’s disease
(4). In addition, a recent study of inflammation arising from
ischemia and perfusion injuries found that many inflammatory
mediators, including IL-1, IL-6, and IL-8, were significantly
reduced in Tnfsrf1a
/
 mice, suggesting that TNF- plays a
primary role in mediating inflammation (1). We found that
pretreatment of SCID-HU-INT mice with the anti-TNF-
monoclonal antibody was very effective in reducing the gut
inflammation seen in amebic colitis in this model. Blockade of
TNF- also reduced the damage to the intestinal permeability
barrier. These data show that TNF- plays a role in the intes-
tinal inflammation and damage to the intestinal permeability
barrier induced by E. histolytica infection. Recent studies indi-
cate that TNF- can directly damage the intestinal permeabil-
ity barrier, offering another mechanism for the efficacy of anti-
TNF- in inhibiting damage to the intestinal permeability
barrier in our model (10). Treatment of SCID-HU-INT mice
with both TNF- and IL-1ra was also effective in reducing
cytokine production, inflammation, and tissue damage in hu-
man colonic xenografts in this model, but we were unable to
detect an additive effect from the use of both immunosuppres-
sants.
While the host inflammatory response mediated by TNF- is
TABLE 1. Human and murine TNF- levels in human colonic
xenografts infected with E. histolytica
Samplea source
Mean TNF- level (pg/ml)  SDb
Human Murine
Untreated mice 68  50 194  163
Anti-TNF--  IL-
1ra-treated mice
28  35 80  66
a E. histolytica-infected human colonic xenograft tissue samples were collected
from groups of 10 untreated or TNF-- and IL-1ra-treated SCID-HU-INT mice.
bThe values for human TNF- differed between untreated and anti-TNF--
and IL-1ra-treated SCID-HU-INT mice at P  0.08. The values for murine
TNF- differed between untreated and anti-TNF-- and IL-1ra-treated SCID-
HU-INT mice at P  0.05.
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clearly linked to tissue damage in this model, blockade of
TNF- does not completely suppress damage to the intestinal
permeability barrier in ameba-infected human colonic xeno-
grafts. FITC-dextran levels were significantly higher in anti-
TNF--treated, E. histolytica-infected human colonic xeno-
grafts than those we detected in uninfected xenografts. Thus,
damage to the colon and its permeability barrier also arises
from tissue injury caused directly by invading E. histolytica
trophozoites, which could be seen in submucosal tissues in all
three experimental groups. Our data are consistent with the
concept that tissue damage in amebic colitis arises from both
the direct effects of E. histolytica on colonic tissue and the
resultant gut inflammatory response, which may be primarily
mediated by TNF-.
This work was supported by National Institutes of Health grants
AI30084 to S.L.S., DK 25274 to the Washington University School of
Medicine Digestive Diseases Research Core Center, and HD 00836 to
the Birth Defects Research Laboratory at the University of Washing-
ton. S.L.S. is a Burroughs Wellcome Scholar in Molecular Parasitol-
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